Shackelford Pharma

Shackelford Pharma

Growth Stage




Raised this Round: Raised: $9,303,845

Total Commitments ($USD)


Dalmore Group

Start Date


Close Date

Not Provided

Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common


Series A

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Vancouver, British Columbia

Business Type


Shackelford Pharma is raising funds on Dalmore Group through Reg A+ crowdfunding. It is an early-stage biopharmaceutical company that aims to develop and commercialize cannabis and hemp-derived CBD-based products. The CBD and cannabis wellness and medical products of Shackelford Pharma will focus on neurocognitive disorders and will be sold through dispensaries, pharmacies, and general retail. Mark Godsy, Dr. Alan Shackelford, and Dr. Avi Livnat founded Shackelford Pharma in 2018. The current crowdfunding campaign has no minimum target and a maximum target of $7,500,000. The campaign proceeds will be used for research and development, sales and marketing, branding, and general and administrative costs.

Balance Sheet

Cash and Cash Equivalents


Investment Securities


Total Investments


Accounts and Notes Receivable




Property, Plant and Equipment (PP&E)


Property and Equipment


Total Assets


Accounts Payable & Accrued Liabilities


Policy Liabilities and Accruals




Long Term Debt


Total Liabilities


Total Stockholders' Equity


Total Liabilities and Equity


Statement of Comprehensive Income Information

Total Revenues


Total Interest Income


Costs & Expenses Applicable to Rev


Total Interest Expenses


Depreciation and Amortization


Net Income


Earnings Per Share - Basic


Earnings Per Share - Diluted


Auditor: Dale Matheson Carr-Hilton Labonte LLP
Financials as of: 04/30/2020
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Shackelford Pharma 12/13/2023 Dealmaker Securities $68,195,651 $833,148 Equity - Common Funded RegA+
Shackelford Pharma 08/19/2021 Dalmore Group $37,595,931 $9,303,845 Equity - Common Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Shackelford Pharma on Dalmore Group 2020
Platform: Dalmore Group
Security Type: Equity - Common
Valuation: $37,595,931
Price per Share: $1.00

Follow company

Follow Shackelford Pharma on Dalmore Group 2020

Buy Shackelford Pharma's Deal Report

Warning: according to the close date for this deal, Shackelford Pharma may no longer be accepting investments.

Shackelford Pharma Deal Report

Get KingsCrowd’s comprehensive report on Shackelford Pharma including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Shackelford Pharma is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Shackelford Pharma deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge